Developed by ![]() ![]() |
Supported by ![]() ![]() |
![]() |
CAB LA and hyaluronidase placeholder
Aqueous drug particle suspension
Subcutaneous, Intramuscular, To be determined
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
NCT06033547
https://clinicaltrials.gov/study/NCT06033547
Phase I
Not provided
ViiV Healthcare
The primary purpose of the study is to investigate the safety, tolerability, and pharmacokinetic (PK) profiles of two different cabotegravir formulations in healthy adult participants. The study will initially start with the assessment of Cabotegravir Formulation F. Once the clinical batch of Cabotegravir Formulation G is available, this formulation will be assessed.
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants
Not provided
Not provided
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2023-09-12
Anticipated Date of Last Follow-up
2025-01-17
Estimated Primary Completion Date
2025-07-25
Estimated Completion Date
2025-07-25
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring * Body weight =\>40 kilogram (kg) and body mass index (BMI) within the range =\>18 to =\<32 kilogram per meter square (kg/m\^2) * Participants who are negative on a single test for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)(approved molecular polymerase chain reaction \[PCR\] laboratory or point of care test) performed on the day of admission. A negative result is required prior to the administration of study intervention on Day 1. * Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical stud
Not provided
Interventional (clinical trial)
56
Not provided
Sequential assignment
Not provided
Open label
Not provided
Not provided
Not provided
Not provided
Not provided
NCT05418868
https://clinicaltrials.gov/study/NCT05418868
Phase I
Recruiting
ViiV Healthcare
This is an open-label, dose-escalation study to investigate the safety, tolerability and pharmacokinetics (PK) of single subcutaneous (SC) administration of long acting (LA) Cabotegravir (CAB) 200 milligrams per milliliter (mg/mL) with Recombinant Human Hyaluronidase PH20 (rHuPH20) (Part A), a single SC or intramuscular (IM) administration of LA CAB (greater than or equal to) \>=400 mg/mL with and without rHuPH20 (Parts C and D), LA CAB Formulation I (Part C Cohort C8) and a single-dose or repeat-dose IM administration of rilpivirine (RPV) (Part E). Part A of the study (CAB 200 mg/mL with rHuPh20) has been closed to further enrolment based on preliminary results.
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
Not provided
Not provided
Not provided
Anticipated Start Date
Not provided
Actual Start Date
2022-06-14
Anticipated Date of Last Follow-up
2025-02-17
Estimated Primary Completion Date
2026-07-06
Estimated Completion Date
2027-11-02
Actual Primary Completion Date
Not provided
Actual Completion Date
Not provided
Age Cohort
Genders
Accepts pregnant individuals
Unspecified
Accepts lactating individuals
Unspecified
Accepts healthy individuals
Yes
Inclusion Criteria: * At the time of obtaining informed consent, participants age should be greater than or equal to (\>=)18 years and less than or equal to (\<=) 55 years. * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Body weight \>=40 kilogram (kg) and body mass index (BMI) within the range \>=18 to \<=32 kilogram per meter square (kg/m\^2). * Participants who are negative on a single test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (approved molecular polymerase chain reaction \[PCR\] laboratory or point of care test), performed on the day of admission. A negative result is required prior to the administration of study intervention on Day 1. * C
Not provided
Interventional (clinical trial)
180
Not provided
Sequential assignment
Not provided
Open label
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL
There are no publication
No documents were uploaded
There are no additional links
|
Collaborate for developmentConsider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology Not provided |
|
Share technical information for match-making assessmentProvide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit Not provided |
|
Work with MPP to expand access in LMICsIn the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing Not provided |
Not provided